CFTR Modulators for the Treatment of Chronic Obstructive Pulmonary Disease: The Jury Is Still Out!

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Refueling T cell memory in cystic fibrosis.American journal of respiratory cell and molecular biology · 2026
   Article
2. Uncovering sodium overload-associated gene signatures in chronic obstructive pulmonary disease through integrated bioinformatics and machine learning.Journal of thoracic disease · 2026
   Article
3. Research Hotspots and Future Trends of Oxygen Therapy for COPD: A Bibliometric and Visualization Analysis from 1973 to 2024.International journal of chronic obstructive pulmonary disease · 2026
   Article
4. Implications for cystic fibrosis therapy: Potentiator icenticaftor is superior to ivacaftor in improving function and maintaining stability of F508del CFTR.Science progress
   Article

Corrections and comments

• Comment on
  Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial.2025

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.